Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reports that it has repurchased 360,000 of its ordinary shares of 31¼ pence each on 20 November 2025, acting through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,755.00p and 1,783.00p per share, with a volume‑weighted average price of 1,766.45p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased a total of 9,958,000 ordinary shares under this programme. After the latest transaction, the company holds 235,422,844 shares in treasury and has 4,080,008,266 ordinary shares in issue, which is also the total number of voting rights. GSK confirms that treasury shares now represent 5.77% of its voting rights.
GSK plc reports that, under its existing share buyback programme, it repurchased 243,000 ordinary shares of 31¼ pence each on 19 November 2025 through BNP Paribas SA. The shares were bought at prices between 1,772.50p and 1,787.00p per share, with a volume‑weighted average price of 1,778.18p, and will be held as treasury shares.
Since 30 September 2025, GSK has repurchased 9,598,000 ordinary shares under this programme. After the latest transaction, GSK holds 235,062,844 shares in treasury and has 4,080,368,266 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by treasury shares is disclosed as 5.76%, helping shareholders calculate any notification thresholds under UK disclosure rules.
GSK plc reported that on 18 November 2025 it transferred 22,000,000 ordinary shares held in treasury to the GlaxoSmithKline Employee Trust, a Jersey resident trust. These shares will be used to satisfy awards under the company’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The trustee paid £17.995 per share, funded by a loan from GlaxoSmithKline Services Unlimited.
After the transfer, GSK holds 234,819,844 ordinary shares in treasury and has 4,080,611,266 ordinary shares in issue, excluding treasury shares. The total number of voting rights is 4,080,611,266, and the percentage of voting rights attributable to treasury shares is 5.75%, which is relevant for shareholders’ disclosure calculations under UK rules.
GSK plc reports that, under its existing share buyback programme, it repurchased 185,000 ordinary shares on 18 November 2025 through BNP Paribas SA. The shares, with a nominal value of 31¼ pence each, were bought at prices between 1,771.00p and 1,803.00p, with a volume-weighted average price of 1,780.45p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 9,355,000 ordinary shares under this programme. After this latest transaction, the company holds 234,819,844 shares in treasury and has 4,080,611,266 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,080,611,266, and the percentage of voting rights attributable to treasury shares is confirmed as 5.75 per cent.
GSK plc reported routine share dealings by senior personnel involving American Depositary Shares (ADSs). On 2025-11-14, Non-Executive Director Dr Hal Barron acquired approximately 2,732.837 notional ADSs in his GSK Executive Supplemental Savings Plan account and 69 ADSs in his GSK 401(k) plan account, both through the reinvestment of dividends at a price of $47.1800 per ADS. On the same date, James Ford, SVP and Group General Counsel, acquired 50.851 notional ADSs in his Executive Supplemental Savings Plan account, also via dividend reinvestment at $47.1800 per ADS. All transactions took place on the New York Stock Exchange.
GSK plc reports that on 17 November 2025 it repurchased 170,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing buyback programme. The shares were bought at prices between 1,781.00p and 1,800.50p per share, with a volume-weighted average price of 1,789.39p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 9,170,000 ordinary shares under this programme. After this transaction, it holds 256,634,844 shares in treasury and has 4,058,796,266 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by treasury shares is stated as 6.32%.
GSK plc reports that on 17 November 2025 it repurchased 170,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing buyback programme. The shares were bought at prices between 1,781.00p and 1,800.50p per share, with a volume-weighted average price of 1,789.39p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 9,170,000 ordinary shares under this programme. After this transaction, it holds 256,634,844 shares in treasury and has 4,058,796,266 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by treasury shares is stated as 6.32%.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 170,000 ordinary shares of 31¼ pence each on 14 November 2025 as part of its existing share buyback programme, at a volume-weighted average price of 1,788.23p per share, with prices ranging from 1,777.00p to 1,807.50p.
The repurchased shares will be held as treasury shares. Since 30 September 2025, the company has bought back a total of 9,000,000 ordinary shares under this programme.
After this transaction, GSK holds 256,464,844 shares in treasury and has 4,058,966,266 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.32% of the voting rights attributable to ordinary shares.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 170,000 ordinary shares of 31¼ pence each on 14 November 2025 as part of its existing share buyback programme, at a volume-weighted average price of 1,788.23p per share, with prices ranging from 1,777.00p to 1,807.50p.
The repurchased shares will be held as treasury shares. Since 30 September 2025, the company has bought back a total of 9,000,000 ordinary shares under this programme.
After this transaction, GSK holds 256,464,844 shares in treasury and has 4,058,966,266 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.32% of the voting rights attributable to ordinary shares.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 167,000 ordinary shares on 13 November 2025 as part of its existing programme. Prices ranged from 1,794.50p to 1,817.50p with a volume‑weighted average price of 1,806.51p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 8,830,000 ordinary shares under the programme. After this purchase, GSK holds 256,294,844 shares in treasury and has 4,059,133,530 ordinary shares in issue (excluding treasury). Total voting rights are 4,059,133,530, and treasury-held voting rights represent 6.31%.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 167,000 ordinary shares on 13 November 2025 as part of its existing programme. Prices ranged from 1,794.50p to 1,817.50p with a volume‑weighted average price of 1,806.51p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 8,830,000 ordinary shares under the programme. After this purchase, GSK holds 256,294,844 shares in treasury and has 4,059,133,530 ordinary shares in issue (excluding treasury). Total voting rights are 4,059,133,530, and treasury-held voting rights represent 6.31%.
GSK plc reported routine insider share acquisitions by multiple senior executives under its Share Reward Plan. The transactions covered Ordinary Shares of 31 ¼ pence each (ISIN: GB00BN7SWP63) at £18.1420 per share on the London Stock Exchange.
Participants included CEO Emma Walmsley and CFO Julie Brown, each acquiring 14 Ordinary Shares (7 partnership and 7 matching). Other executives—James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte—also acquired 14 shares each on 2025-11-11. David Redfern acquired 12 shares (6 partnership and 6 matching). These are standard plan-related purchases disclosed via Form 6-K.
GSK plc reported routine insider share acquisitions by multiple senior executives under its Share Reward Plan. The transactions covered Ordinary Shares of 31 ¼ pence each (ISIN: GB00BN7SWP63) at £18.1420 per share on the London Stock Exchange.
Participants included CEO Emma Walmsley and CFO Julie Brown, each acquiring 14 Ordinary Shares (7 partnership and 7 matching). Other executives—James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte—also acquired 14 shares each on 2025-11-11. David Redfern acquired 12 shares (6 partnership and 6 matching). These are standard plan-related purchases disclosed via Form 6-K.